

14<sup>th</sup> November, 2025

To,  
The Manager - Corporate Relationship  
Dept.  
BSE Limited  
P. J. Towers, Dalal Street  
Fort, Mumbai - 400 001

To,  
The Manager - Corporate Compliance  
National Stock Exchange of India Limited  
Exchange Plaza, Plot No.C-1,  
G Block, BKC, Bandra (E),  
Mumbai 400 051

**BSE Scrip Code: - 524500**

**NSE SYMBOL: - KILITCH**

**Sub: Press Release**

Dear Sir,

Please find enclosed herewith our Press Release relating to H1FY26 financial results of the Company, which we shall be releasing after sending this letter to you.

Request you to take note of the same and acknowledge the receipt.

Thanking you,

Yours' Faithfully,

For **Kilitch Drugs (India) Limited**

**Mukund Mehta**  
**Managing Director**  
**DIN: 00147876**





## Kilitch Drugs' PAT rises by 18% YoY to ₹10.30 crore in H1 FY26

**Mumbai, November 14, 2025:** Kilitch Drugs Limited (BSE – 524500), a leading pharmaceutical company specializing in high-quality parenterals, oral solids and effervescent, announced its unaudited financial results for the half year ended September 30, 2025.

The company reported a Profit After Tax of ₹10.30 crore in H1 FY26, an 18.1% increase compared to ₹8.72 crore in H1 FY25. The growth in profitability was supported by improved operational efficiencies, better product mix and consistent demand across key markets.

Total income for the period stood at ₹101.28 crore, registering a 14.23% YoY growth from ₹88.66 crore in H1 FY25. The company continued to strengthen its presence in domestic and international markets, driven by sustained orders for its parenteral range and increasing traction in oral solids and effervescent formulations.

Commenting on the company's Q2FY26 performance, **Mr. Mukund Mehta, Chairman and Managing Director, Kilitch Drugs Limited**, said, "Our H1FY26 results reflect steady and broad-based growth across our key markets and product segments. The continued demand for our effervescent, injectable formulation including oral solid dosage formulations, coupled with operational efficiency, has supported our profitability. We remain committed to sustainable growth, and long-term value creation for our stakeholders.

With a healthy order pipeline and steady demand outlook, the company expects business momentum to remain positive in the second half of FY26.

During the quarter ended 30 September 2025, the Company successfully completed a rights issue of 13,98,463 fully paid-up equity shares of face value ₹10 each, issued at ₹357 per share (including a premium of ₹347). The issue aggregated to ₹4992.51 lakh and was primarily undertaken to fund the capital expenditure for its upcoming Greenfield Project at Pen. These equity shares were allotted on 25 August 2025. This infusion strengthens the company's balance sheet and supports its long-term expansion plans.

### About Kilitch Drugs (India) Ltd:

Incorporated in 1992, Kilitch Drugs (India) Ltd is a leading pharmaceutical manufacturing company with existing manufacturing units in Mumbai, India, Ethiopia (Africa) and setting up a new green field project in Pen, Maharashtra India, which aims to develop and manufacture various pharmaceuticals including Injectables, Ophthalmic, OSD and Nutraceuticals, meeting regulatory requirements along with USFDA to approach across the globe. The company is a global innovator and has been consistently recognized for its excellence in quality, innovative processes, research and development, and sustainable product portfolio. Kilitch Drugs India Ltd has successfully established a foothold across several key African countries. Its manufacturing plant in Mumbai is equipped with specialized sections for dry powder formulations, small-volume liquid ampoules, and vials. The company's facilities are certified by multiple global authorities, including WHO GMP, ISO 9001, ISO 13485, PPB Kenya, NAFDAC Nigeria, FDA Ghana, MOH Sudan, Phillipines Pix Approvals, EFDA Ethiopia and many other countries. The company's product portfolio spans a wide range of therapeutic areas, including antibacterial, gastroenterology, anti-inflammatory, anti-malarial, ophthalmic, uterine stimulants, veterinary medicines, and many more.

### **For media queries, please contact:**

| Name         | Email Id   | Mobile No      |
|--------------|--|----------------|
| Meeral Salia | <a href="mailto:meeral.s@sgal.net">meeral.s@sgal.net</a>         | +91 7738364559 |
| Ira Dhingra  | <a href="mailto:ira.dhingra@sgapl.net">ira.dhingra@sgapl.net</a> | +91 8700973450 |
| Utsa Saha    | <a href="mailto:utsa.saha@sgapl.net">utsa.saha@sgapl.net</a>     | +91 9051508252 |